Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;106:1154-1158
Published online before print August 5, 2002, doi: 10.1161/01.CIR.0000026820.87824.6A
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/9/1154    most recent
01.CIR.0000026820.87824.6Av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forgione, M. A.
Right arrow Articles by Loscalzo, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forgione, M. A.
Right arrow Articles by Loscalzo, J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Genetically altered mice
Right arrow Ischemic biology - basic studies
Right arrow Oxidant stress
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2002;106:1154.)
© 2002 American Heart Association, Inc.


Basic Science Reports

Heterozygous Cellular Glutathione Peroxidase Deficiency in the Mouse

Abnormalities in Vascular and Cardiac Function and Structure

Marc A. Forgione, MD; Andre Cap, PhD; Ronglih Liao, PhD; Nicanor I. Moldovan, PhD; Robert T. Eberhardt, MD; Chee Chew Lim, PhD; John Jones, MD; Pascal J. Goldschmidt-Clermont, MD; Joseph Loscalzo, MD, PhD

From Evans Department of Medicine (M.A.F., R.L., R.T.E., C.C.L., J.L.), Department of Surgery (J.J.), and Whitaker Cardiovascular Institute (M.A.F., A.C., R.L., C.C.L., R.T.E., J.J., J.L.), Boston University School of Medicine, Boston, Mass; Cardiology Section, Department of Medicine (N.M.), The Ohio State University, Columbus, Ohio; and Duke University School of Medicine (P.G.), Durham, NC.

Correspondence to Dr Loscalzo, Boston University School of Medicine, 715 Albany St, W507, Boston, MA 02118. E-mail jloscalz{at}bu.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background— Oxidant stress has been implicated in the pathogenesis of atherothrombosis and other vascular disorders accompanied by endothelial dysfunction. Glutathione peroxidases (GPx) play an important role in the cellular defense against oxidant stress by utilizing glutathione (GSH) to reduce lipid hydroperoxides and hydrogen peroxide to their corresponding alcohols. Cellular GPx (GPx-1) is the principal intracellular isoform of GPx. We hypothesized that GPx-1 deficiency per se induces endothelial dysfunction and structural vascular abnormalities through increased oxidant stress.

Methods and Results— A murine model of heterozygous deficiency of GPx-1 (GPx+/-) was investigated to examine this hypothesis. Mesenteric arterioles in GPx-1+/- mice demonstrated vasoconstriction to acetylcholine compared with vasodilation in wild-type mice (maximal change in vessel diameter, -13.0±2.8% versus 13.2±2.8%, P<0.0001). We also noted an increase in the plasma and aortic levels of the isoprostane iPF2{alpha}-III, a marker of oxidant stress, in GPx-1+/- mice compared with wild-type mice (170.4±23 pg/mL plasma versus 98.7±7.1 pg/mL plasma, P<0.03; 11.7±0.87 pg/mg aortic tissue versus 8.2±0.55 pg/mg aortic tissue, P<0.01). Histological sections from the coronary vasculature of GPx-1+/- mice show increased perivascular matrix deposition, an increase in the number of adventitial fibroblasts, and intimal thickening. These structural abnormalities in the myocardial vasculature were accompanied by diastolic dysfunction after ischemia-reperfusion.

Conclusions— These findings demonstrate that heterozygous deficiency of GPx-1 leads to endothelial dysfunction, possibly associated with increased oxidant stress, and to significant structural vascular and cardiac abnormalities. These data illustrate the importance of this key antioxidant enzyme in functional and structural responses of the mammalian cardiovascular system.


Key Words: endothelium • vasculature • antioxidants • oxygen • nitric oxide


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Nitric oxide (NO) synthesized by the endothelium represents an important regulatory determinant of vascular function. This short-lived endothelial product promotes vasodilation,1 impairs platelet activation and leukocyte adherence to the endothelium,2 preserves the barrier function of the endothelium,3 and acts as an antioxidant.4 Oxidant stress, associated with an increase in reactive oxygen species in the vasculature, promotes NO insufficiency and the ensuing endothelial dysfunction.5

Reduced glutathione (GSH) plays an important role in the cellular defense against oxidant stress.6 GSH is an essential cosubstrate for the glutathione peroxidases (GPx), selenocysteine-containing proteins that reduce lipid peroxides (LOOH) and hydrogen peroxide to their corresponding alcohols.7 Peroxyl radicals generated from LOOH can inactivate NO through the formation of lipid peroxynitrites.8 GPxs exist in at least 4 different isoforms. GPx-1 is the most abundant and ubiquitous intracellular isoform, and the expression of this enzyme is significantly suppressed by a known risk factor for atherothrombosis, ie, homocysteine.9,10 Because GSH represents one of the most important intracellular antioxidants, primarily in its role as a cosubstrate for GPx-1, we propose that this antioxidant system plays a central role in protecting the vasculature in states of increased oxidant stress.

Recently, targeted gene disruption of GPx-1 has been achieved in the mouse.7 To assess the vascular consequences of oxidant stress per se on vascular homeostasis, we investigated the effect of heterozygous GPx-1 deficiency on endothelium-dependent vascular function, oxidant stress, and cardiovascular function and structure in this murine model.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Reagents and Animals
ß-Methacholine (BMC), bradykinin, and sodium nitroprusside (SNP) were obtained from Sigma Chemical Co. Mice homozygous for disruption of the GPx-1 gene were kindly provided by Y. Ho at Wayne State University (Detroit, Mich) and subsequently bred at our institution.

GPx-1 was inactivated by insertion of a neomycin resistance gene cassette into an EcoRI site located in exon 2 of the GPx-1 gene, which was then inserted into mouse embryonic stem cells, as previously described.7 Heterozygous (+/-) GPx-1–deficient male mice and littermate, wild-type (+/+) (WT) control male mice were used at 40 to 60 weeks of age for the experiments assessing function. The animals were fed standard chow and handled secondary to National Institutes of Health guidelines. The Institutional Animal Care and Use Committee at Boston University Medical Center approved the procedures.

Genotype Determination
DNA was obtained by extraction from mouse tail snips. One microliter of DNA was amplified in 50-µL polymerase chain reaction (PCR) containing 10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, 1.5 mmol/L MgCl2, 0.001% gelatin, 0.1 mmol/L dNTPs, and 0.18 µmol/L of each primer. To identify the WT GPx-1 gene, we used the forward primer FinN (5'-GTTTCCCGTGCAATCAGTTCG–3') and the reverse primer R3N (5'-TCGGACGTACTTGAG- GGAAT-3') to amplify a 293-bp fragment. To detect the neomycin resistance gene cassette present in GPx-1+/- mice, we used FinN and RpgkN (5'-CATTTGTCACGTCCTGCAC-3') as the reverse primer to amplify a 509-bp fragment in the neomycin resistance insert. Reaction products were analyzed by electrophoresis on a 1% agarose gel. GPx-1+/- mice were identified by having both a 509-bp PCR product and a 293-bp PCR product; WT mice were identified by an exclusive 293-bp PCR product. Genotype was correlated with phenotype by measuring GPx-1 activity in cardiac or vascular tissue extracts, as previously described.11 GPx-1+/- mice had 48±4% of the activity of GPx-1+/+ mice.

Mesenteric Microcirculation Studies
Mice were anesthetized with pentobarbital (0.04 mg/kg) by intraperitoneal injection, then intubated and ventilated with 100% oxygen. Vascular reactivity in the mesenteric circulation was assessed in vivo using videomicroscopy,12 as previously described.13 The mesentery was placed on a heated microscope stage and superfused with saline, ß-methacholine, bradykinin, or sodium nitroprusside, and the mesenteric arteriolar response to these agents was monitored by quantitative videomicroscopic measurement. In some experiments, Cu,Zn superoxide dismutase was superfused at 150 U/mL to evaluate the effect of this agent on endothelial dysfunction in response to 10-6 mol/L methacholine.

Measurement of Isovolumic Contractile Performance
Hearts were isolated and perfused in the Langendorff model, as previously described, with minor modifications.14 Briefly, mice were injected intraperitoneally with heparin (10 000 U/kg) and anesthetized with a combination of ketamine (150 mg/kg) and xylazine (15 mg/kg). The thorax was rapidly opened, and the heart was excised and arrested in ice-cold saline. A short perfusion cannula was inserted into the aortic root to initiate retrograde perfusion. The hearts were perfused with Krebs-Henseleit buffer (in mmol/L, NaCl 118, KCl 4.7, CaCl2 1.9, KH2PO4 1.2, MgSO4 1.2, NaHCO3 24.0, and glucose 10.0) equilibrated with 95% O2 and 5% CO2 yielding a pH of 7.4. The pulmonary artery was cannulated with a thin polyethylene tube (PE-50) for collection of coronary effluent. A thin cannula was pierced through the apex of the left ventricle (LV) to vent Thebesian drainage. A small balloon, custom-made from polyvinyl chloride film and connected to 5-cm polyethylene tubing (PE 50; internal diameter 0.58 mm), was inserted into the LV through the mitral valve via an incision in the left atrium. The balloon was specifically designed to ensure that the unstressed volume and inherent compliance of the balloon were greater than those of the ventricle for accurate assessment of ventricular pressure. No discernible pressure drop was detected over the length of the tubing. The balloon was connected to a pressure transducer (Statham P23Db, Gould) for recording LV pressures. Previous experiments have determined no discernible damping of the pressure signal with balloon-derived ventricular pressures relative to direct transducer-tipped catheter-derived ventricular pressures, over heart rates from 0 to 7 Hz and over a range of ventricular pressures from 0 to 100 mm Hg. The balloon was inflated with H2O to adjust the end-diastolic pressure (EDP) at 10 mm Hg (balloon volume, 35.8±1.5 µL and 36.5±1.1 µL for WT and GPx-1+/- mice, respectively), and the balloon volume was held constant for the duration of the experiment. Hearts were paced (Grass Instruments) through platinum wires placed on the epicardial surface of the right ventricle. Coronary perfusion pressure (CPP) was monitored via a sidearm of the aortic cannula connected to a pressure transducer (Stratham P23Db, Gould). An inline ultrasonic flow probe (Transonics Systems, Inc) was positioned immediately above the aortic cannula to measure coronary blood flow. Systolic pressure and EDP, heart rate, CPP, and coronary blood flow were collected online at rates of 400 samples/sec using a commercially available data acquisition system (MacLab ADInstruments). Developed pressure (DevP), ie, the difference between systolic and diastolic pressures, was calculated offline. DevP was used as an index of contractile performance and EDP as an index of diastolic function.

After instrumentation, all hearts were stabilized for 15 minutes at 37°C at a CPP of 80 mm Hg and paced at 7 Hz. Throughout the duration of the experiment, myocardial temperature was held constant at 37°C via careful temperature regulation of the myocardial perfusate and submersion of the heart in Krebs-Henselseit buffer warmed by a water-jacketed chamber. Hearts were then subjected to 15 minutes of zero-flow ischemia followed by 30 minutes of reperfusion. The pacer was turned off during ischemia and turned on again 15 minutes into reperfusion.

Isoprostane Determination
Mice were sacrificed and plasma and thoracic aortas were obtained by centrifugation of blood collected in tubes containing 0.1 mol/L (final concentration) EDTA. Samples were then snap-frozen in liquid nitrogen and stored at -80°C. Plasma was diluted 1:15 in ultrapure water (Cayman Chemical Co), applied to a reverse-phase C-18 column (Alltech), pH=3.0, and eluted with 50/50% (vol/vol) ethyl acetate/hexane. The eluent was then additionally purified on a silica column (Alltech) and eluted with 50/50% (vol/vol) ethyl acetate/hexane. Measurement of iPF2{alpha}-III was then made using a commercially available immunoassay (Cayman Chemical Co). Aortic tissue was minced, and iPF-III was extracted as previously described.11

cGMP Determination
cGMP content was measured in isolated thoracic aortas, as previously described.11

Histological Assessment
Tissue, including heart, aorta, and mesentery, was excised from 6 GPx-1+/- and 6 WT mice between 40 to 60 weeks of age immediately after the animals were euthanized. The tissues were fixed in 4% formalin and embedded in paraffin, and the sections were stained with hematoxylin and eosin as well as Masson trichrome.

Statistics
Data were analyzed using the Students’ t test or (repeated measures) ANOVA with post-hoc comparisons where appropriate. P<0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Mesenteric Vascular Reactivity
Superfusion of BMC produced dose-dependent vasodilation of mesenteric arterioles in WT mice (Figure 1). There was a maximal 13.2±2.8% increase in arteriolar diameter while superfusing BMC 10-4 mol/L. In contrast, mesenteric arterioles from GPx-1+/- mice manifested dose-dependent vasoconstriction to BMC. There was a maximal 13±2.8% decrease in vessel diameter while superfusing BMC at 10-4 mol/L, which was significantly different compared with the response of WT mice (P<0.0001). This paradoxical vasoconstriction to BMC is indicative of impaired endothelium-dependent vasodilation in GPx-1+/- mice involving the microcirculation, consistent with a depletion of bioavailable NO. Similar results were obtained using bradykinin as another endothelium-dependent agonist, ie, paradoxical vasoconstriction in GPx-1+/- mice compared with dose-dependent vasodilation in WT mice (data not shown).



View larger version (12K):
[in this window]
[in a new window]
 
Figure 1. Mesenteric microvascular response to superfusion of ß-methacholine in WT mice ({blacksquare}) (n=6) and GPx-1+/- mice ({bullet}) (n=4) at 40 to 60 weeks of age. §P<0.0001 for total response; *P<0.001 for individual doses by post-hoc Newman-Keuls comparisons.

Superfusion of 150 U/mL Cu,Zn superoxide dismutase converted a -7.2% (vasoconstriction) response into a +5.5% (vasodilator) response at 10-6 mol/L methacholine. Superfusion of SNP resulted in dose-dependent vasodilation in both GPx-1+/- and WT mice (Figure 2), with no significant difference in the response between the two groups. Therefore, endothelium-independent vasodilation in the microcirculation of GPx-1+/- mice is preserved.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 2. Mesenteric microvascular response to superfusion of sodium nitroprusside in WT mice ({blacksquare}) (n=5) and GPx-1+/- mice ({bullet}) (n=5) at 40 to 60 weeks of age. §P=NS.

Aortic cGMP Levels
Aortic tissue from GPx-1+/- mice accumulated less cGMP with 1 µmol/L acetylcholine stimulation for 1 minute compared with aortic tissue from WT mice (0.50±0.02 versus 0.90±0.10 pmol/mg tissue, P<0.01).

Cardiac Function
Figure 3A shows the developed pressure (DevP) during the course of the ischemia-reperfusion protocol. At baseline, DevP was similar between GPx-1+/- and WT hearts. At the onset of zero-flow ischemia, DevP dropped quickly to zero in both groups. Under reperfusion, there was a gradual recovery of DevP with no difference in recovery between groups during the course of reperfusion. These data demonstrate that partial inactivation of GPx-1 did not result in any worse recovery of contractile performance after ischemia-reperfusion compared with WT hearts.



View larger version (35K):
[in this window]
[in a new window]
 
Figure 3. Left ventricular developed pressure (DevP) (A) and EDP (B) measured under isovolumic conditions in WT+/+ (WT; {bullet}, n=6), and GPx-1+/- ({triangleup}, n=6) mouse hearts at baseline and during 15 minutes of ischemia followed by 30 minutes of reperfusion. The shaded box represents the Ischemic period. *P<0.05 by repeated ANOVA during the reperfusion period.

With global (zero-flow) ischemia, Figure 3B shows that EDP gradually rose during the course of the ischemic period. Immediately on reperfusion, EDP increased to a maximum of 81.5±4.3 mm Hg in WT and 99.7±6.6 mm Hg in GPx-1+/- hearts (P<0.05). EDP gradually decreased during the course of reperfusion in both groups; however, GPx-1+/- hearts exhibited worse diastolic function, as shown by a greater EDP compared with WT hearts. Total coronary flow was comparable between groups at baseline and reperfusion (baseline WT, 3.3±0.1 mL/min; GPx+/-, 2.8±0.4 mL/min; reperfusion WT, 1.3±0.1 mL/min; and GPx+/-, 1.3±0.1 mL/min). These data suggest that GPx-1+/- hearts are more susceptible to diastolic dysfunction secondary to ischemia-reperfusion injury.

iPF2{alpha}-III Levels
There was a 172% increase in plasma levels of iPF2{alpha}-III in GPx-1+/- mice (170.4±23.0 pg/mL, n=5) compared with WT mice (98.7±7/1 pg/mL, n=5) (P<0.03) and a 43% increase in aortic iPF2{alpha}-III in GPx-1+/- mice (11.7±0.87 pg/mg tissue, n=3) compared with WT mice (8.2±0.55 pg/mg tissue, n=3) (P<0.01).

Histological Assessment
We noted striking changes in the vasculature of GPx+/- mice compared with WT mice, as illustrated in Figure 4. Both interstitial and perivascular fibrosis were observed in the myocardium of GPx+/- mice (Figures 4A and 4B). Abundant periadventitial inflammation was also noted (Figure 4C), as was neointima formation (Figures 4D and 4E). Extensive collagen deposition was observed surrounding the epicardial coronary arteries, as well (Figure 4F), implicating the presence of abundant fibroblasts of a synthetic phenotype. No such changes were apparent in WT mice (data not shown).



View larger version (143K):
[in this window]
[in a new window]
 
Figure 4. Vascular histology. A, Myocardium and intramyocardial coronary artery in a 50-week-old WT mouse (Mallory trichrome stain). B, Perivascular and interstitial fibrosis in a 50-week-old GPx+/- mouse (EVG stain). C, Abundant periadventitial inflammation and fibrosis of a right ventricular intramyocardial artery in a GPx+/- mouse (hematoxylin and eosin stain). D, Parallel section as in panel C, showing prominent neointima in the same intramyocardial artery (arrow indicates location of the internal elastic lamina). E, Neointima and degenerating media in the same vessel as panels C and D, shown at higher power (Mallory trichrome stain). F, Extensive collagen deposition around a left ventricular epicardial artery in a GPx+/- mouse. Original magnifications: A and F, x80; B, x120; C and D, x20; and E, x200.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Previous studies have supported a relationship between decreased GPx activity and vascular injury. GPx-1 activity is decreased in atherosclerotic plaques excised from patients with carotid artery disease,15 and hyperhomocysteinemia is associated with a significant reduction in GPx-1 expression,9,10 indicating that a change in the expression of this enzyme may contribute to vascular oxidant stress and the progression of atherothrombosis. Pharmacological inhibition of GPx-1 by 50% is associated with an increased flux of reactive oxygen species and low-density lipoprotein oxidation.16 Selenium deficiency is associated with a decrease in GPx-1 activity in rats,17 and dietary selenium supplementation increases GPx-1 activity in the aorta and liver of rats.18 Patients with selenium deficiency have an increased incidence of coronary artery disease19 and a decrease in GPx-1 activity. These data are consistent with the requirement for dietary selenium in the synthesis of selenocysteine-containing proteins such as GPx-1. Taken together, these observations suggest that the selenocysteine-containing protein GPx-1 serves an important role in protecting the vasculature from oxidant stress. Our findings of endothelial dysfunction, increased oxidant stress, and abnormal vascular structural changes in older mice with heterozygous deficiency of GPx-1 support this hypothesis.

Mesenteric vessels from mice with heterozygous GPx-1 deficiency demonstrate paradoxical vasoconstriction to methacholine and bradykinin superfusion. In addition, cGMP levels in response to stimulation with a muscarinic agonist were significantly lower in GPx-1+/- mice compared with WT mice. This result suggests that the endothelial dysfunction develops as a result of a deficiency of bioactive NO in the presence of GPx-1 deficiency. Importantly, there was no difference in the arteriolar response to SNP, a direct vasodilator, between WT and GPx-1+/- mice, indicating that the endothelial dysfunction in GPx-1+/- mice is not a result of nonspecific impairment of vascular smooth muscle function.

Oxidant stress plays an important role in the development and progression of atherothrombosis. Isoprostanes are formed by the nonenzymatic reaction of free radicals with arachidonic acid. The isoprostane iPF2{alpha}-III has been identified as a marker of increased oxidant stress in several conditions associated with atherothrombosis, including diabetes mellitus, 20 cigarette use,21 and hypercholesterolemia.22,23 The increase in iPF2{alpha}-III in the plasma and aortas of GPx-1+/- mice suggests that increased oxidant stress occurs as a result of a deficiency of this important antioxidant enzyme. Although there are some data in vitro to support the production of iPF2{alpha}-III in a cyclooxygenase-dependent fashion,24,25 this mechanism is not supported by recent patient data.20,21,26 Taken together with the improvement in endothelial function after mesenteric superfusion with Cu,Zn superoxide dismutase, these data showing impaired endothelium-dependent NO-mediated endothelial function in the setting of increased oxidant stress in the vasculature suggest that bioactive NO may be decreased by interaction with reactive oxygen species, whose inactivation is limited by GPx-1 deficiency.

Heterozygous deficiency of GPx-1 is also associated with impaired cardiac function after ischemia-reperfusion injury. In contrast to a prior published report,27 we failed to find any abnormality in contractile performance after ischemia-reperfusion injury; however, we report for the first time an abnormality in diastolic dysfunction accompanying recovery from no-flow ischemia. This abnormal diastolic function may be a consequence of intramyocardial vascular dysfunction, cardiomyocyte dysfunction, regional differences in the severity of ischemia, changes in myocardial turgor, or a combination of these effects resulting from inadequate intracellular GPx-1 pools. That GPx-1 is present in much higher concentrations in the heart than is catalase, has a lower Michaelis constant for hydrogen peroxide than catalase, and reduces lipid peroxides as well as hydrogen peroxide28 suggests that this enzyme is critical for the protection of the myocardium against oxidant stress.

The heart and vasculature of GPx-1+/- animals is subject to greater injury and dysfunction, not only by the profound oxidant stress of acute ischemia-reperfusion injury but also by low-level oxidant stress occurring throughout the lifetime of these animals. This point is clearly illustrated by the increase in basal levels of F2-isoprostanes as well as the profound histologic changes observed in the myocardium and myocardial vasculature.

Histological sections from coronary arteries and aorta from these older GPx-1+/- mice show increased perivascular matrix deposition and adventitial fibroblasts, as well as inflammatory cells and intimal thickening, when compared with WT mice. These vascular lesions may be indicative of the damage caused to the vasculature by the increased oxidant stress accompanying lifelong partial GPx-1 deficiency. These lesions are reminiscent of changes noted in the aging process, but are significantly more marked, suggesting that the GPx-1+/- mouse may serve as a model of aging for cardiovascular studies and supporting a relationship between the cumulative effects of free radical-based oxidant injury and the aging process.29,30

In summary, heterozygous GPx-1 deficiency results in impaired endothelium-dependent vascular relaxation in resistance vessels and abnormal diastolic function in hearts subject to ischemia-reperfusion injury. GPx-1 deficiency causes increased oxidative stress, as measured by elevations of plasma iPF2{alpha}-III. The vasculature and myocardium of these animals demonstrate increased perivascular matrix deposition and fibrosis, as well as intimal thickening. We conclude that GPx-1 deficiency per se causes increased oxidant stress, which impairs endothelial and cardiomyocyte function and leads to structural vascular and cardiac abnormalities.


*    Acknowledgments
 
This work was supported in part from National Institutes of Health grants HL 55993, HL 58976, and HL 61795. M.A. Forgione and J. Jones were supported by National Institutes of Health Cardiovascular Training Grant HL 07224-24. We thank Stephanie Tribuna and Katherine Seropian for their assistance in the preparation of this manuscript and Anne Ward Scribner for her technical assistance.

Received April 29, 2002; revision received May 31, 2002; accepted June 3, 2002.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995; 95: 1747–1755.[Medline] [Order article via Infotrieve]
  2. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987; 148: 1482–1489.[CrossRef][Medline] [Order article via Infotrieve]
  3. Kurose I, Kubes P, Wolf R, et al. Inhibition of nitric oxide production: mechanisms of vascular albumin leakage. Circ Res. 1993; 73: 164–171.[Abstract]
  4. Rubbo H, Darley-Usmar V, Freeman BA. Nitric oxide regulation of tissue free radical injury. Chem Res Toxicol. 1996; 9: 809–820.[CrossRef][Medline] [Order article via Infotrieve]
  5. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995; 332: 512–521.[Free Full Text]
  6. Raes M, Michiels C, Remacle J. Comparative study of the enzymatic defense systems against oxygen-derived free radicals: the key role of glutathione peroxidase. Free Rad Biol Med. 1987; 3: 3–7.[CrossRef][Medline] [Order article via Infotrieve]
  7. Ursini F, Maiorino M, Brigelius-Flohe R, et al. Diversity of glutathione peroxidases. Meth Enzymol. 1995; 252: 38–53.[Medline] [Order article via Infotrieve]
  8. Rubbo H, Radi R, Trujillo M, et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation: formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem. 1994; 269: 26066–26075.[Abstract/Free Full Text]
  9. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997; 272: 10712–10717.
  10. Outinen PA, Sood SK, Pfeifer SI, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood. 1999; 94: 959–967.[Abstract/Free Full Text]
  11. Forgione MA, Weiss N, Heydrick S, et al. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol. 2002; 282: H1255–H1261.
  12. Suzuki H, Zweifach BW, Schmid-Schonbein GW. Vasodilator response of mesenteric arterioles to histamine in spontaneously hypertensive rats. Hypertension. 1995; 26: 397–400.[Abstract/Free Full Text]
  13. Eberhardt RT, Forgione MA, Cap AP, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000; 106: 483–491.[Medline] [Order article via Infotrieve]
  14. Lim CC, Liao R, Varma N, et al. Impaired lusitropy-frequency in the aging mouse: role of Ca2+-handling proteins and effects of isoproterenol. Am J Physiol. 1999; 277: H2083–H2090.[Medline] [Order article via Infotrieve]
  15. Lapenna D, de Gioia S, Ciofani G, et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation. 1998; 97: 1930–1934.[Abstract/Free Full Text]
  16. Rosenblat M, Aviram M. Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL: in vitro and in vivo studies. Free Radic Biol Med. 1998; 24: 305–317.[CrossRef][Medline] [Order article via Infotrieve]
  17. Moriarty PM, Reddy CC, Maquat LE. Selenium deficiency reduces the abundance of mRNA for Se-dependent glutathione peroxidase 1 by a UGA-dependent mechanism likely to be nonsense codon-mediated decay of cytoplasmic mRNA. Mol Cell Biol. 1998; 18: 2932–2939.[Abstract/Free Full Text]
  18. Kang BP, Bansal MP, Mehta U. Selenium supplementation and diet induced hypercholesterolemia in the rat: changes in lipid levels, malonyldialdehyde production and the nitric oxide synthase activity. Gen Physiol Biophys. 1998; 17: 71–78.[Medline] [Order article via Infotrieve]
  19. Salonen JT, Alfthan G, Huttunen JK, et al. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet. 1982; 2: 175–179.[Medline] [Order article via Infotrieve]
  20. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2{alpha} and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999; 99: 224–229.[Abstract/Free Full Text]
  21. Reilly M, Delanty N, Lawson JA, et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996; 94: 19–25.[Abstract/Free Full Text]
  22. Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-Epi-prostaglandin F2 {alpha} is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997; 17: 3230–3235.[Abstract/Free Full Text]
  23. Reilly MP, Praticó D, Delanty N, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998; 98: 2822–2828.[Abstract/Free Full Text]
  24. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 {alpha}. J Biol Chem. 1995; 270: 9800–9808.[Abstract/Free Full Text]
  25. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2{alpha} by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996; 271: 8919–8924.[Abstract/Free Full Text]
  26. Pratico D, Barry OP, Lawson JA, et al. IPF2{alpha}-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A. 1998; 95: 3449–3454.[Abstract/Free Full Text]
  27. Yoshida T, Maulik N, Engleman RM, et al. Glutathione peroxidase knockout mice are susceptible to myocardial ischemia reperfusion injury. Circulation. 1996; 96 (suppl II): II-216–II-220.
  28. Le CT, Hollaar L, Van der Valk EJM, et al. Buthionine sulfoximide reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack. J Mol Cell Cardiol. 1993; 25: 519–528.[CrossRef][Medline] [Order article via Infotrieve]
  29. Ashok BT, Ali R. The aging paradox: free radical theory of aging. Exp Gerontol. 1999; 34: 293–303.[CrossRef][Medline] [Order article via Infotrieve]
  30. Mori A, Utsumi K, Liu J, et al. Oxidative damage in the senescence-accelerated mouse. Ann N Y Acad Sci. 1998; 854: 239–250.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
FASEB J.Home page
J. L. Tarry-Adkins, M. S. Martin-Gronert, J.-H. Chen, R. L. Cripps, and S. E. Ozanne
Maternal diet influences DNA damage, aortic telomere length, oxidative stress, and antioxidant defense capacity in rats
FASEB J, June 1, 2008; 22(6): 2037 - 2044.
[Abstract] [Full Text] [PDF]


Home page
Ann Clin BiochemHome page
M. Kerkeni, F. Added, M. B. Farhat, A. Miled, F. Trivin, and K. Maaroufi
Hyperhomocysteinaemia and parameters of antioxidative defence in Tunisian patients with coronary heart disease
Ann Clin Biochem, March 1, 2008; 45(2): 193 - 198.
[Abstract] [Full Text] [PDF]


Home page
Epidemiol RevHome page
S. Musaad and E. N. Haynes
Biomarkers of Obesity and Subsequent Cardiovascular Events
Epidemiol. Rev., May 10, 2007; (2007) mxm005v1.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Torzewski, V. Ochsenhirt, A. L. Kleschyov, M. Oelze, A. Daiber, H. Li, H. Rossmann, S. Tsimikas, K. Reifenberg, F. Cheng, et al.
Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 850 - 857.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
Z. Cao, H. Zhu, L. Zhang, X. Zhao, J. L. Zweier, and Y. Li
Antioxidants and Phase 2 Enzymes in Cardiomyocytes: Chemical Inducibility and Chemoprotection Against Oxidant and Simulated Ischemia-Reperfusion Injury
Experimental Biology and Medicine, September 1, 2006; 231(8): 1353 - 1364.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. B. de Haan, P. K. Witting, N. Stefanovic, J. Pete, M. Daskalakis, I. Kola, R. Stocker, and J. J. Smolich
Lack of the antioxidant glutathione peroxidase-1 does not increase atherosclerosis in C57BL/J6 mice fed a high-fat diet
J. Lipid Res., June 1, 2006; 47(6): 1157 - 1167.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
N. Ardanaz and P. J. Pagano
Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction.
Experimental Biology and Medicine, March 1, 2006; 231(3): 237 - 251.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Haendeler and S. Dimmeler
Inseparably Tied: Functional and Antioxidative Capacity of Endothelial Progenitor Cells
Circ. Res., February 3, 2006; 98(2): 157 - 158.
[Full Text] [PDF]


Home page
Circ. Res.Home page
G. Galasso, S. Schiekofer, K. Sato, R. Shibata, D. E. Handy, N. Ouchi, J. A. Leopold, J. Loscalzo, and K. Walsh
Impaired Angiogenesis in Glutathione Peroxidase-1-Deficient Mice Is Associated With Endothelial Progenitor Cell Dysfunction
Circ. Res., February 3, 2006; 98(2): 254 - 261.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. A. Leopold and J. Loscalzo
Oxidative Enzymopathies and Vascular Disease
Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1332 - 1340.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Schnabel, K. J. Lackner, H. J. Rupprecht, C. Espinola-Klein, M. Torzewski, E. Lubos, C. Bickel, F. Cambien, L. Tiret, T. Munzel, et al.
Glutathione Peroxidase-1 and Homocysteine for Cardiovascular Risk Prediction: Results from the AtheroGene Study
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1631 - 1637.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Zhang, D. E. Handy, and J. Loscalzo
Adenosine-Dependent Induction of Glutathione Peroxidase 1 in Human Primary Endothelial Cells and Protection Against Oxidative Stress
Circ. Res., April 29, 2005; 96(8): 831 - 837.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
R. Stocker and J. F. Keaney Jr.
Role of Oxidative Modifications in Atherosclerosis
Physiol Rev, October 1, 2004; 84(4): 1381 - 1478.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. Hamanishi, H. Furuta, H. Kato, A. Doi, M. Tamai, H. Shimomura, S. Sakagashira, M. Nishi, H. Sasaki, T. Sanke, et al.
Functional Variants in the Glutathione Peroxidase-1 (GPx-1) Gene Are Associated With Increased Intima-Media Thickness of Carotid Arteries and Risk of Macrovascular Diseases in Japanese Type 2 Diabetic Patients
Diabetes, September 1, 2004; 53(9): 2455 - 2460.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Y. Oudit, M. G. Trivieri, N. Khaper, T. Husain, G. J. Wilson, P. Liu, M. J. Sole, and P. H. Backx
Taurine Supplementation Reduces Oxidative Stress and Improves Cardiovascular Function in an Iron-Overload Murine Model
Circulation, April 20, 2004; 109(15): 1877 - 1885.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Jain, L. Cui, D. A. Brenner, B. Wang, D. E. Handy, J. A. Leopold, J. Loscalzo, C. S. Apstein, and R. Liao
Increased Myocardial Dysfunction After Ischemia-Reperfusion in Mice Lacking Glucose-6-Phosphate Dehydrogenase
Circulation, February 24, 2004; 109(7): 898 - 903.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Taniyama and K. K. Griendling
Reactive Oxygen Species in the Vasculature: Molecular and Cellular Mechanisms
Hypertension, December 1, 2003; 42(6): 1075 - 1081.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Blankenberg, H. J. Rupprecht, C. Bickel, M. Torzewski, G. Hafner, L. Tiret, M. Smieja, F. Cambien, J. Meyer, K. J. Lackner, et al.
Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients with Coronary Artery Disease
N. Engl. J. Med., October 23, 2003; 349(17): 1605 - 1613.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Miura, J. J. Bosnjak, G. Ning, T. Saito, M. Miura, and D. D. Gutterman
Role for Hydrogen Peroxide in Flow-Induced Dilation of Human Coronary Arterioles
Circ. Res., February 7, 2003; 92 (2): e31 - e40.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/9/1154    most recent
01.CIR.0000026820.87824.6Av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar